vs
Adaptive Biotechnologies Corp（ADPT）与REPUBLIC BANCORP INC（RBCAA）财务数据对比。点击上方公司名可切换其他公司
REPUBLIC BANCORP INC的季度营收约是Adaptive Biotechnologies Corp的1.3倍（$94.3M vs $71.7M），REPUBLIC BANCORP INC净利率更高（24.2% vs -18.9%，领先43.2%），Adaptive Biotechnologies Corp同比增速更快（51.0% vs 5.3%），REPUBLIC BANCORP INC自由现金流更多（$161.1M vs $1.4M），过去两年Adaptive Biotechnologies Corp的营收复合增速更高（30.8% vs -11.5%）
ExpreS2ion Biotechnologies是一家丹麦生物技术企业，总部位于丹麦霍尔斯霍姆，专注于新型疫苗和免疫疗法产品的研发，在纳斯达克第一北增长市场瑞典板块挂牌上市。
肯塔基州共和银行是美国的一家区域性银行控股企业，提供零售及商业银行全品类服务，涵盖个人存贷款、企业融资、按揭产品及财富管理解决方案，主要服务肯塔基州及周边州的个人消费者和中小企业客户。
ADPT vs RBCAA — 直观对比
营收规模更大
RBCAA
是对方的1.3倍
$71.7M
营收增速更快
ADPT
高出45.7%
5.3%
净利率更高
RBCAA
高出43.2%
-18.9%
自由现金流更多
RBCAA
多$159.7M
$1.4M
两年增速更快
ADPT
近两年复合增速
-11.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $71.7M | $94.3M |
| 净利润 | $-13.6M | $22.8M |
| 毛利率 | 74.6% | — |
| 营业利润率 | -17.8% | 29.3% |
| 净利率 | -18.9% | 24.2% |
| 营收同比 | 51.0% | 5.3% |
| 净利润同比 | 59.7% | 20.0% |
| 每股收益（稀释后） | $-0.08 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADPTRBCAA
| Q4 25 | $71.7M | $94.3M | ||
| Q3 25 | $94.0M | $93.5M | ||
| Q2 25 | $58.9M | $93.8M | ||
| Q1 25 | $52.4M | $135.8M | ||
| Q4 24 | $47.5M | $89.5M | ||
| Q3 24 | $46.4M | $88.1M | ||
| Q2 24 | $43.2M | $86.9M | ||
| Q1 24 | $41.9M | $120.3M |
净利润ADPTRBCAA
| Q4 25 | $-13.6M | $22.8M | ||
| Q3 25 | $9.5M | $29.7M | ||
| Q2 25 | $-25.6M | $31.5M | ||
| Q1 25 | $-29.9M | $47.3M | ||
| Q4 24 | $-33.7M | $19.0M | ||
| Q3 24 | $-32.1M | $26.5M | ||
| Q2 24 | $-46.2M | $25.2M | ||
| Q1 24 | $-47.5M | $30.6M |
毛利率ADPTRBCAA
| Q4 25 | 74.6% | — | ||
| Q3 25 | 80.7% | — | ||
| Q2 25 | 69.4% | — | ||
| Q1 25 | 67.6% | — | ||
| Q4 24 | 62.0% | — | ||
| Q3 24 | 64.1% | — | ||
| Q2 24 | 55.3% | — | ||
| Q1 24 | 56.9% | — |
营业利润率ADPTRBCAA
| Q4 25 | -17.8% | 29.3% | ||
| Q3 25 | 10.9% | 40.4% | ||
| Q2 25 | -42.5% | 43.0% | ||
| Q1 25 | -56.4% | 44.1% | ||
| Q4 24 | -71.3% | 25.8% | ||
| Q3 24 | -70.3% | 38.4% | ||
| Q2 24 | -109.6% | 37.0% | ||
| Q1 24 | -116.5% | 32.2% |
净利率ADPTRBCAA
| Q4 25 | -18.9% | 24.2% | ||
| Q3 25 | 10.2% | 31.8% | ||
| Q2 25 | -43.5% | 33.5% | ||
| Q1 25 | -56.9% | 34.8% | ||
| Q4 24 | -71.0% | 21.2% | ||
| Q3 24 | -69.1% | 30.1% | ||
| Q2 24 | -107.0% | 29.0% | ||
| Q1 24 | -113.5% | 25.4% |
每股收益（稀释后）ADPTRBCAA
| Q4 25 | $-0.08 | — | ||
| Q3 25 | $0.06 | — | ||
| Q2 25 | $-0.17 | — | ||
| Q1 25 | $-0.20 | — | ||
| Q4 24 | $-0.22 | — | ||
| Q3 24 | $-0.22 | — | ||
| Q2 24 | $-0.31 | — | ||
| Q1 24 | $-0.33 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $70.5M | $220.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $218.8M | $1.1B |
| 总资产 | $512.7M | $7.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ADPTRBCAA
| Q4 25 | $70.5M | $220.0M | ||
| Q3 25 | $55.0M | $484.2M | ||
| Q2 25 | $43.2M | $484.8M | ||
| Q1 25 | $50.6M | $793.0M | ||
| Q4 24 | $47.9M | $432.2M | ||
| Q3 24 | $38.1M | $530.9M | ||
| Q2 24 | $59.8M | $400.1M | ||
| Q1 24 | $71.2M | $546.4M |
股东权益ADPTRBCAA
| Q4 25 | $218.8M | $1.1B | ||
| Q3 25 | $204.4M | $1.1B | ||
| Q2 25 | $179.7M | $1.1B | ||
| Q1 25 | $190.4M | $1.0B | ||
| Q4 24 | $202.7M | $992.0M | ||
| Q3 24 | $223.8M | $979.7M | ||
| Q2 24 | $241.6M | $955.4M | ||
| Q1 24 | $274.9M | $935.6M |
总资产ADPTRBCAA
| Q4 25 | $512.7M | $7.0B | ||
| Q3 25 | $490.6M | $7.0B | ||
| Q2 25 | $496.6M | $7.0B | ||
| Q1 25 | $510.9M | $7.1B | ||
| Q4 24 | $539.4M | $6.8B | ||
| Q3 24 | $558.5M | $6.7B | ||
| Q2 24 | $584.9M | $6.6B | ||
| Q1 24 | $620.3M | $6.9B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.1M | $168.2M |
| 自由现金流经营现金流 - 资本支出 | $1.4M | $161.1M |
| 自由现金流率自由现金流/营收 | 2.0% | 170.9% |
| 资本支出强度资本支出/营收 | 0.9% | 7.5% |
| 现金转化率经营现金流/净利润 | — | 7.37× |
| 过去12个月自由现金流最近4个季度 | $-48.9M | $288.6M |
8季度趋势，按日历期对齐
经营现金流ADPTRBCAA
| Q4 25 | $2.1M | $168.2M | ||
| Q3 25 | $-7.1M | $33.3M | ||
| Q2 25 | $-12.4M | $8.4M | ||
| Q1 25 | $-28.5M | $93.2M | ||
| Q4 24 | $-12.5M | $149.0M | ||
| Q3 24 | $-27.1M | $51.3M | ||
| Q2 24 | $-17.3M | $4.0M | ||
| Q1 24 | $-38.4M | $71.2M |
自由现金流ADPTRBCAA
| Q4 25 | $1.4M | $161.1M | ||
| Q3 25 | $-7.5M | $30.8M | ||
| Q2 25 | $-13.1M | $5.2M | ||
| Q1 25 | $-29.7M | $91.6M | ||
| Q4 24 | $-12.6M | $143.2M | ||
| Q3 24 | $-27.4M | $49.8M | ||
| Q2 24 | $-19.0M | $2.7M | ||
| Q1 24 | $-39.9M | $69.1M |
自由现金流率ADPTRBCAA
| Q4 25 | 2.0% | 170.9% | ||
| Q3 25 | -8.0% | 32.9% | ||
| Q2 25 | -22.2% | 5.5% | ||
| Q1 25 | -56.7% | 67.4% | ||
| Q4 24 | -26.5% | 160.0% | ||
| Q3 24 | -59.0% | 56.5% | ||
| Q2 24 | -44.1% | 3.1% | ||
| Q1 24 | -95.2% | 57.5% |
资本支出强度ADPTRBCAA
| Q4 25 | 0.9% | 7.5% | ||
| Q3 25 | 0.4% | 2.6% | ||
| Q2 25 | 1.1% | 3.5% | ||
| Q1 25 | 2.4% | 1.2% | ||
| Q4 24 | 0.2% | 6.5% | ||
| Q3 24 | 0.7% | 1.7% | ||
| Q2 24 | 4.0% | 1.5% | ||
| Q1 24 | 3.6% | 1.7% |
现金转化率ADPTRBCAA
| Q4 25 | — | 7.37× | ||
| Q3 25 | -0.75× | 1.12× | ||
| Q2 25 | — | 0.27× | ||
| Q1 25 | — | 1.97× | ||
| Q4 24 | — | 7.84× | ||
| Q3 24 | — | 1.93× | ||
| Q2 24 | — | 0.16× | ||
| Q1 24 | — | 2.33× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADPT
| Mrd Business Segment | $61.9M | 86% |
| Immune Medicine Business | $9.8M | 14% |
| Immune Medicine Service Revenue | $100.0K | 0% |
RBCAA
暂无分部数据
